Johnson & Johnson (JNJ)

3,529.23
-63.97(-1.78%)
  • Volume:
    192
  • Bid/Ask:
    3,529.23/3,580.00
  • Day's Range:
    3,528.24 - 3,578.00
  • Type:Equity
  • Market:Mexico
  • ISIN:US4781601046
  • S/N:478160104

JNJ Overview

Prev. Close
3,593.2
Day's Range
3,528.24-3,578
Revenue
-
Open
3,578
52 wk Range
3,205-3,799.98
EPS
-
Volume
192
Market Cap
9.37T
Dividend (Yield)
4.52
(2.54%)
Average Vol. (3m)
1,076
P/E Ratio
-
Beta
-
1-Year Change
3.5%
Shares Outstanding
2,631,401,804
Next Earnings Date
-
What is your sentiment on J&J?
or
Market is currently closed. Voting is open during market hours.

Johnson & Johnson News

Johnson & Johnson Analysis

Johnson & Johnson Company Profile

Johnson & Johnson Company Profile

Employees
141700

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company’s Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellBuy
Technical IndicatorsNeutralSellStrong SellStrong SellStrong Buy
SummarySellStrong SellStrong SellStrong SellStrong Buy
  • vaccines are problematic. High penalties will come from lawsuits. stock markets are falling. However, the stock is going up. god *****share
    0
    • Tomorrow is earnings report . Let wait for report.. if below forcast we can short it on cfd ... Also the company is paying $99m to West Virginia..... That a negative report I guess...
      1
      • I want to buy
        2
        • The Fed's minutes from the January meeting, set to be released on Wednesday, will return focus to monetary policy, and the prospect of aggressive rate hikes ahead. 
          0
          • JnJ is buy and hold dude, enjoy divis. It grows slowly in a sustainable way
            1
            • thought tho that jnj will be on a good buy this season as they are about to improve on there vaccines
              0
              • to buy or not?????
                1
                • will JnJ Breakout @KC?
                  0
                  • Hello
                    0
                • Window of (buy) opportunity just closed...
                  0
                  • Hello
                    0
                • Window of (buy) opportunity just closed...
                  0